Evaluating a new oral treatment for moderate traumatic brain injury.
Preclinical Efficacy and Safety Evaluation of Oral AST-004 for Moderate Traumatic Brain Injury (TBI)
This study is testing a new oral medication called AST-004 to see if it can help people with moderate traumatic brain injuries recover better by protecting brain cells and improving healing.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Astrocyte Pharmaceuticals, INC. NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-11185453 on NIH RePORTER |
What this research studies
This research focuses on the development of AST-004, a small molecule designed to be administered orally to patients with moderate traumatic brain injury (TBI). The study aims to assess the safety and effectiveness of AST-004 in protecting brain cells and improving recovery outcomes. By targeting astrocytes, a type of brain cell that plays a crucial role in healing, the research seeks to enhance mitochondrial function and reduce damage caused by TBI. Patients participating in this research may receive a novel treatment that could significantly improve their recovery process.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who have sustained a moderate traumatic brain injury.
Not a fit: Patients with mild or severe traumatic brain injuries may not benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to a new therapeutic option that improves recovery and reduces long-term disabilities associated with moderate TBI.
How similar studies have performed: Previous research has shown promise in targeting astrocytes for neuroprotection, indicating that this approach may lead to successful outcomes.
Where this research is happening
Cambridge, United States
- Astrocyte Pharmaceuticals, INC. — Cambridge, United States (Active)
Researchers
- Principal investigator: Liston, Theodore E — Astrocyte Pharmaceuticals, INC.
- Study coordinator: Liston, Theodore E
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.